CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
← catalyst calendarNCT07335497 · readout ≤ 924 d
Sponsored by Crescent Biopharma, Inc. (industry) · CBIO — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
290estimated
Sites
28
Countries
Australia, Ireland, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-17 | actual | When the study began enrolling |
| Primary completion | Feb 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced / Metastatic Solid Tumors
Intervention
- Drug: CR-001
Primary outcomes
what the primary-completion date above is the date OFDose Escalation - Incidence and nature of dose-limiting toxicities
measured From the first dose of study drug up until approximately 1 month
Dose Escalation - Characterization of the maximum tolerated dose, if applicable
measured From the first dose of study drug up until approximately 1 month
All parts - Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment - emergent serious adverse events
measured From the first dose of study drug until 90 days after the last dose of study drug
All parts - Incidence and severity of TEAEs leading to dose modifications
measured From the first dose of study drug until 90 days after the last dose of study drug
All parts - Incidence and severity of TEAEs leading to treatment discontinuation
measured From the first dose of study drug until 90 days after the last dose of study drug
Permalink · CBIO's whole pipeline · Catalyst calendar · Every registered study · What changed